GLOBAL LIVER INSTITUTE
Dr. Kelly Brownell, Dean Emeritus of the Sanford School of Public Policy at Duke University, has over 35 years of experience studying food systems and obesity. After initially focusing on obesity treatments, he found that weight loss often led to rapid regain, suggesting a harmful metabolic change.
As the founder and CEO of Global Liver Institute (GLI), and a liver transplant patient myself, I know it is imperative to connect the dots between real-world experiences of patients and policy solutions.
Today marks the seventh annual Global Fatty Liver Day (formerly International NASH Day), led by Global Liver Institute (GLI) with the theme “Act Now, Screen Today.” This campaign underscores the crucial need for early identification and treatment of fatty liver disease to prevent its progression to chronic liver disease, cirrhosis, or cancer.
Global Liver Institute applauds U.S. Representative Nydia Velázquez (D-NY) for reintroducing this vital legislation to improve the lives of all people impacted by liver disease. GLI was proud to collaborate in the development of The Liver Illness, Visibility, Education and Research Act (LIVER Act), first introduced in 2018.
GLI responds to VA efforts to deny or delay access to NASH/MASH treatment while proactively pushing for Congress to advance policies that support access to comprehensive care for liver disease patients.
Nonalcoholic fatty liver disease (NAFLD or more recently metabolic dysfunction-associated steatotic liver disease, MASLD) has long been associated with obesity, but researchers are beginning to look into the trend that a sizable portion of those with the disease actually has a “normal” or lean weight.
Over the past decade, the prevalence of metabolic dysfunction-associated steatotic liver disease (MASLD, previously known as nonalcoholic fatty liver disease/NAFLD) in children has seen a concerning rise.
The GLI Pediatric and Rare Liver Diseases team was thrilled to attend the BARE Symposium on May 10-11, 2024.
June 13 marks Global Fatty Liver Day, and the time to act is NOW! With conditions like obesity and diabetes increasing the risk for fatty liver disease, early screening is absolutely crucial.
Fatty liver disease includes a spectrum of liver conditions characterized by excess fat accumulation in the liver of individuals. It encompasses a range of conditions, from simple steatosis (fatty liver) to nonalcoholic steatohepatitis (NASH), as well as nonalcoholic fatty liver disease (NAFLD) which can progress to cirrhosis, liver failure, and hepatocellular carcinoma.
Genentech/Roche is enhancing the accessibility of clinical trials by providing comprehensive patient support services. By tackling common barriers to participation – such as travel costs, distance, parking, childcare, conflicting work schedules, health literacy, site location, capabilities, expectations, and privacy concerns – they aim to make clinical trials more inclusive and representative.
Global Liver Institute applauds U.S. Representative Nydia Velázquez (D-NY) for reintroducing this vital legislation to improve the lives of all people impacted by liver disease. GLI was proud to collaborate in the development of The Liver Illness, Visibility, Education and Research Act (LIVER Act), first introduced in 2018.
